Oslo, Norway, 26 April 2012
Clavis Pharma ASA (OSE: CLAVIS), the cancer-focused drug
development company, is hosting Capital Markets Days for
members of the financial community, press and other
interested parties, in New York City, USA and Oslo, Norway
in May.
The time schedules for the Capital Markets Days are as
follows:
New York City, USA - Wednesday 23 May, 2012
07:30am Eastern Time (registration/breakfast)
08:00 - 10:30am ET (presentations & Q&A)
Speakers:
Dr. Farhad Ravandi,
Associate Professor, Department of Leukemia
MD Anderson Cancer Center, University of
Texas
Dr. Jennifer Spratlin,
Assistant Professor of Medical Oncology
Cross Cancer Institute, University of Alberta
Additional speakers include members of Clavis Pharma's
senior management team.
For more information and to RSVP please contact:
Peter Rahmer at prahmer@troutgroup.com
or Simon Harnest at sharnest@troutgroup.com
***
Oslo, Norway - Wednesday 30 May, 2012
07:30am CET (registration/breakfast)
08:00 - 11.00am CET (presentations & Q&A)
Speakers:
Dr. Oliver G. Ottmann
Department of Hematology/Oncology, Johann Wolfgang
Goethe-University, Frankfurt
Dr. Emmet McCormack
Department of Hematology, Institute of Internal
Medicine, University of Bergen
Dr. David Cotterell
Managing Director, APEX Healthcare Consulting
Additional speakers include members of Clavis Pharma's
senior management team.
For more information and to RSVP, please contact:
Bente Y. Robertsen at bente.robertsen@clavispharma.com
or Nina Enegren at nina.enegren@citigatedr.co.uk
****
Contacts:
Olav Hellebų
Chief Executive Officer
+47 24 11 09 50
olav.hellebo@clavispharma.com
Gunnar Manum
Chief Financial Officer
+47 24 11 09 71
+47 95 17 91 90 (mob)
gunnar.manum@clavispharma.com
Mark Swallow / Nina Enegren / David Dible (International
media enquiries)
Citigate Dewe Rogerson
+44 207 282 2948
clavispharma@citigatedr.co.uk
Peter Rahmer (US Investor enquiries)
The Trout Group
+1 646 378 2973 Direct / + 646 272 8526 Cell
prahmer@troutgroup.com
****
About Clavis Pharma
Clavis Pharma ASA is a clinical-stage oncology focused
pharmaceutical company based in Oslo, Norway with a
portfolio of novel anti-cancer drugs in development. These
patented New Chemical Entities (NCEs) are novel, improved
versions of commercially successful drugs, made using
Clavis Pharma's Lipid Vector Technology (LVT)
chemistry. Data generated suggests these potential
breakthrough products may offer improved efficacy and
reduced side effects through enhanced pharmacokinetic
properties, greater tissue penetration, altered metabolism
and, in certain cases, additional modes of action.
Clavis Pharma's has several drug candidates in
development:
-
Elacytarabine, a leukaemia drug, currently in a
randomized, controlled Phase III study in relapsed or
refractory acute myeloid leukaemia;
-
CP-4126, is currently in a pivotal clinical study
compared to gemcitabine for the 1st line treatment of
metastatic pancreatic cancer and a Phase II trial for 2nd
line treatment for pancreatic cancer in patients
refractory to 1st line gemcitabine treatment;
-
CP-4200, an azacitidine derivative, in preclinical
development for myelodysplastic syndrome (MDS), a disease
that is often a precursor to leukaemia.
Clavis Pharma intends to commercialise its products through
strategic alliances and partnerships with experienced
oncology businesses and, where and when commercially
appropriate, by establishing its own sales and marketing
capabilities.
Recommend:
